INI, at doses used in human clinical trials to treat patients with T2DM, AD, and mild cognitive impairment, does not significantly alter the blood levels of insulin or glucose, which indicates that there is a little risk of acute hypoglycemic episodes that can occur with subcutaneous and intravenous insulin injections, which may be dangerous [25,26,27,28,29]. The gene discussed is INS; the disease is Cognitive impairment.